6541 fundamentals
An in-depth look to TANVEX BIOPHARMA INC operating, investing, and financing activities
6541 free cash flow for Q1 24 is -328.35 M TWD. For 2023, 6541 free cash flow was -1.5 B TWD and operating cash flow was -1.43 B TWD.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: TWD
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM